^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

GD2-CART01

i
Other names: GD2-CART01, iC9-GD2-CAR T cells
Associations
Trials
Company:
Bambino Gesu Hospital
Drug class:
GD2-targeted CAR-T immunotherapy
Associations
Trials
10ms
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk And/or Relapsed/refractory Neuroblastoma or Other GD2-positive Solid Tumors (clinicaltrials.gov)
P1/2, N=42, Active, not recruiting, Bambino Gesù Hospital and Research Institute | Trial primary completion date: Dec 2024 --> Dec 2026 | Recruiting --> Active, not recruiting
Enrollment closed • Trial primary completion date
|
GD2-CART01